These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21592231)

  • 1. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
    Epailly E; Albanell J; Andreassen A; Bara C; Campistol JM; Delgado JF; Eisen H; Fiane AE; Mohacsi P; Schubert S; Sebbag L; Turazza FM; Valantine H; Zuckermann A; Potena L
    Clin Transplant; 2011; 25(5):E475-86. PubMed ID: 21592231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ
    Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
    Klintmalm GB; Saab S; Hong JC; Nashan B
    Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V; Castro C; Campistol JM
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical recommendations for the use of everolimus in heart transplantation.
    Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
    Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK
    Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
    Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
    Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E; Kushwaha SS
    Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of atrial arrhythmias after heart or double-lung transplantation at a single center: insights into the mechanism of post-operative atrial fibrillation.
    Dizon JM; Chen K; Bacchetta M; Argenziano M; Mancini D; Biviano A; Sonett J; Garan H
    J Am Coll Cardiol; 2009 Nov; 54(22):2043-8. PubMed ID: 19926011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of proliferation signal inhibitors in post-transplant malignancies.
    Gutiérrez-Dalmau A; Campistol JM
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
    Gaumann A; Schlitt HJ; Geissler EK
    Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.